certainly transformed health care
and life sciences. But organizations would need to look at how
the disruptive technologies can
work in tandem to drive meaningful transformation and provide
value. Many companies are still
in the experimental stage when it
comes to digital. To realize their
full potential and keep pace with
technology’s rapid evolution, regulation of these technologies needs
to become more agile.
Mobilizing data, the
currency of life sciences
Forward-looking life sciences
leaders who have adopted digital
platforms and emerging tech-
nologies are measuring value and
outcomes with greater efficacy. Big
Data driven insights can dramati-
cally transform patient care and
enhance productivity of trials.
R&D seems to have embarked on a
new journey with the digital wave
where trials are less burdensome
and more engaging. Patients are
collaborators during clinical trials
and not just passive participants.
The emergence of virtual clini-
cal trials has eliminated the need
for travel, thereby, expanding the
geographical reach and accessibil-
ity from a patient-care point of
view. R&D executives are placing
greater emphasis on the role of
Real-World Evidence (RWE) and
focusing on end-to-end, AI-driv-
en, internally-developed solutions.
See Chart 8.
In 2019, the early adopters of
digital technologies and platforms
could benefit from better engagement with patients, deeper insights
from clinical trials, and faster cycle
times for products in development.
Creating value with new
business and operating
Digitally maturing biopharma
companies are exploring ways of
applying an enterprise-wide ap-
Transformative technologies in life sciences
Artificial intelligence (AI)
Valued at US$41.2 billion in 2017, the
IoMT market is expected to rise to
US$158.1 billion in 2022
The potential to revolutionize
diagnoses, treatment planning, patient
monitoring, and drug discovery
Potential solution to more easily aggregate
and share health data in a secure, trusted,
automated, and error-free way
Allows patients to play a more active role
in their own health care
SaMD has, at times, outperformed the
accuracy of diagnoses by trained clinicians
Regulation of SaMD is expected to need
to become more agile
DIY diagnostics and
Consumers are increasingly open to new
channels of care—particularly at-home
Could help low-income or rural
consumers determine if a condition
warrants a visit to a doctor or hospital
Shifting attitudess toward mobility
and changing the way people and
Could improve access to care
Future of mobility
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are
legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see www.deloitte.com/about for a more detailed description of DTTL and its member firms.
Deloitte provides audit, consulting, financial advisory, risk management, tax and related services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than
150 countries and territories,
Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte’s more than 200,000 professionals are committed
to becoming the standard of excellence.
This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the “Deloitte Network”) is, by means of this publication, rendering
professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall
be responsible for any loss whatsoever sustained by any person who relies on this publication.
About Life Sciences and Health Care at Deloitte Touche Tohmatsu Limited
The Deloitte Touche Tohmatsu Limited’s life sciences and health care (LSHC) industry group is composed of more than 12,000 professionals in more than 90 countries. These member firm professionals understand the
complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across
the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
For more information about the DTTL LSHC industry group, email email@example.com or access www.deloitte.com/lifesciencesoutlook.
©2019. For more information, contact Deloitte Touche Tohmatsu Limited.